stockrow
Friday 6 November 2026
Export PLUR’s income statement to Excel — free account
Pluri Inc.
PLUR Healthcare Biotechnology
Pluri Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.0 million, down 24.0% from fiscal 2025.
- Revenue
- −15.8%
- EPS
- +44.8%
- Free cash flow
- +25.0%
- Total debt
- +3.43%
Quarter to June 2026, against a year earlier
1.24
0.05
+4.20%
Follow PLUR
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
20.04 | 31.68 | 20.68 | 30.39 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.58) | (7.58) | (5.32) | (7.42) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
40.12 | 48.64 | 32.16 | 58.30 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.08) | (2.58) | (2.14) | (3.95) | |
EV/FCF |
(2.02) | (2.42) | (1.96) | (3.66) | |
Quick Ratio |
0.24 | 0.30 | 0.40 | 0.49 | |
Current Ratio |
0.27 | 0.33 | 0.43 | 0.53 | |
Net Debt/EBITDA |
(3.76) | (2.85) | (2.41) | (1.94) | |
Debt/Assets |
113.45% | 106.85% | 91.78% | 81.79% | |
Debt/Equity |
(1.62) | (2.14) | (3.05) | (4.88) | |
Asset Turnover |
0.03 | 0.03 | 0.04 | 0.04 | |
Operating CF/Net income |
0.76 | 0.81 | 0.80 | 0.93 | |
Capex/Depreciation |
(0.06) | (0.34) | (3.47) | (0.89) | |
Interest Coverage |
(23.60) | (27.58) | (28.16) | (27.73) | |
Research and Development Expense of Revenue |
1,006.87% | 2,372.46% | 1,932.32% | 1,243.99% | |
Selling, General and Administrative Expense of Revenue |
707.16% | 1,574.85% | 1,396.97% | 801.90% | |
Intangible Assets out of Total Assets |
0.23 | 0.22 | 0.19 | 0.17 | |
Share Based Compensation of Revenue |
142.09% | 680.84% | 385.35% | 427.22% | |
Graham Net Nets |
(1.65) | (0.84) | (0.94) | (0.56) | |
Graham Number |
9.93 | 9.16 | 8.57 | 6.61 | |
Earnings Yield |
(117.22%) | (84.93%) | (109.62%) | (69.14%) | |
Free Cash Flow Yield |
(99.20%) | (63.44%) | (79.51%) | (52.36%) | |
Revenue per Share |
0.03 | 0.02 | 0.02 | 0.04 | |
Operating CF per Share |
(0.46) | (0.45) | (0.56) | (0.60) | |
Capex per Share |
0.00 | 0.00 | (0.05) | (0.01) | |
Free Cash Flow per Share |
(0.46) | (0.45) | (0.61) | (0.62) | |
Cash per Share |
0.80 | 0.95 | 1.37 | 1.72 | |
Shareholders Equity per Share |
(1.79) | (1.29) | (0.99) | (0.63) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.79) | (1.29) | (0.99) | (0.63) | |
Free Cash Flow |
(4.45) | (4.56) | (5.65) | (5.54) | |
Working Capital |
(23.99) | (21.54) | (18.54) | (15.24) | |
Capital Expenditures |
(0.01) | (0.04) | (0.45) | (0.12) | |
Net Current Asset Value |
(33.58) | (28.59) | (26.00) | (22.40) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.26 | 2.26 | 0.37 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.16 | 0.14 | 0.15 | 0.16 | |
Average Payables |
2.29 | 2.15 | 2.36 | 2.24 | |
Average Assets |
31.78 | 31.73 | 30.73 | 34.56 | |
Average Common Equity |
(9.15) | (6.26) | (6.06) | (2.85) |
Columns are period end dates · fundamentals updated 25 Oct 2026